眼科创新力量代表再获超亿元融资，加速国产高端眼科器械进口替代进程

Company Overview - SierraMedical, an innovative domestic ophthalmic medical device company, recently completed a new financing round exceeding 100 million yuan, led by Qianji Capital and Shunwei Capital, with existing shareholders Bohang Capital and Honghui Fund increasing their stakes [1] - Founded in July 2022, SierraMedical integrates research and development, production, and sales, focusing on providing precise and intelligent minimally invasive surgical solutions for ophthalmology [3] Product Development - The financing will primarily support the deep development of the company's first self-developed phacoemulsification and vitrectomy integrated machine product line, while also enriching the company's ophthalmic surgical equipment product matrix [1] - SierraMedical has launched the NEXVIT® series of ultra-high-speed dual-blade dual-gas path vitreous cutting heads, achieving a cutting speed of up to 20,000 cuts per minute, which has been clinically validated for performance and safety [3] - The company is also developing a disposable ophthalmic puncture device that features a slanted front cut and a chamfered design to assist surgeons in making precise and safe incisions, minimizing damage to surrounding eye tissue [4] Market Potential - The ophthalmic medical device market in China reached a scale of 45 billion yuan in 2023, with a compound annual growth rate exceeding 15%, significantly higher than the global average [3] - SierraMedical aims to break the monopoly of foreign companies in the high-end ophthalmic surgical instrument sector and address critical instrument supply issues [3] Investment Insight - Qianji Capital and Shunwei Capital, both leading investors in this financing round, have a strong track record in the medical field, with Qianji Capital being one of the earliest specialized funds in healthcare and life sciences in China [6]